Navigation Links
BioNanomatrix Appoints Michael Kochersperger as Vice President of Engineering
Date:1/9/2009

-Brings Broad Expertise and Strong Leadership Skills in Developing and Refining Innovative Life Sciences Systems-

PHILADELPHIA, Jan. 9 /PRNewswire/ -- BioNanomatrix, Inc., a developer of breakthrough nanoscale platforms for molecular diagnostics, personalized medicine and biomedical research, today announced the appointment of Michael Kochersperger as vice president of engineering. Mr. Kochersperger has over two decades of product development and commercialization experience at leading life sciences tools companies. He will lead the team focusing on the commercial design and development of BioNanomatrix's breakthrough nanoscale whole genome imaging and analysis system for multiple markets, including research, diagnostics and personalized medicine.

"Michael is an exceptional addition to the BioNanomatrix leadership team," said Dr. Michael Boyce-Jacino, chief executive officer of BioNanomatrix. "He has broad product-focused engineering expertise combined with a record of success in delivering innovative life sciences systems to market on time and within budget. Michael's engineering experience and leadership skills will be invaluable as we focus on developing commercial versions of our nanoscale whole genome imaging and analysis technology."

BioNanomatrix is applying its expertise in nanochips, nanodevices and nanosystems to develop its platform technology providing fast, comprehensive and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Among its current development efforts is a federally funded project in partnership with Complete Genomics Inc. for very low-cost sequencing of the human genome.

"BioNanomatrix's technology has the potential to be transformative, allowing scientists to analyze genomic material much faster, more cost-effectively and with far better accuracy and resolution than existing methods," said Mr. Kochersperger. "I look forward to working with the BioNanomatrix team to commercialize products based on our revolutionary technology, which has the potential to make whole genome imaging and analysis accessible for the first time for a wide range of research and diagnostic applications."

Prior to joining BioNanomatrix, Michael was vice president of engineering at New Brunswick Scientific, a division of Eppendorf, where he oversaw global product development efforts, helping to revitalize the company's entire product portfolio in less than six years. Previously, he was director of SNP-IT genotyping research and development at Orchid Biosciences, where he led the development and commercialization of ultra-high-throughput microarray-based genotyping systems. Prior to Orchid, Michael was project manager for the development of a combinatorial chemistry synthesis system at Applera. Previously, he was project team lead for protein sequencing system development at Perkin Elmer, where he oversaw the development and improvement of several systems. Earlier, Michael was at Applied Biosystems, where he held positions of increasing responsibility, managing mass spectrometry and protein sequencing projects and providing technical support. He has authored a number of scientific publications and holds three patents. Michael received a B.S. in chemical engineering from Ohio State University.

About BioNanomatrix

BioNanomatrix is developing breakthrough nanoscale whole genome imaging and analytic platforms for applications in genetic diagnostics, personalized medicine and biomedical research. The company is applying its expertise in nanochips, nanodevices and nanosystems to develop its patented platform technology to provide fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Its current development efforts include a federally funded project to sequence the human genome at a cost of $100. BioNanomatrix's technologies are licensed exclusively from Princeton University. Founded in 2003, the company is headquartered in Philadelphia, Pennsylvania. For more information, visit: www.BioNanomatrix.com.

    Contact:
    Barbara Lindheim
    GendeLLindheim BioCom Partners
    212 918-4650


'/>"/>
SOURCE BioNanomatrix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis
2. BioNanomatrix Receives New NCI Grant to Support Development of Chip-Based Nanofluidics Systems for Cell Fractionation
3. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
4. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
5. BioNanomatrix Announces Appointment of Paul R. Selvin to Its Scientific Advisory Board
6. BioNanomatrix Awarded New NIH Grant for Development of Nanoscale Platform for Single-Molecule DNA Mapping and Haplotype Applications
7. BioNanomatrix Announces Appointment of Dr. Pui-Yan Kwok to Its Scientific Advisory Board
8. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
9. Codexis Appoints Singapore Laboratories Managing Director
10. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
Breaking Biology News(10 mins):